Publications by authors named "M E Dottorini"
Background: Female thyroid cancer survivors are more likely to have a higher risk of breast cancer compared to the general population, and the underlying causes are yet to be understood. The potential role of I-131 treatment on this association remains controversial.
Methods: We pooled individual data of women who were treated for differentiated thyroid cancer from 1934 to 2005 in France, Italy and Sweden.
Prevalence of interstitial pneumonia suggestive of COVID-19 at F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study.
Eur J Nucl Med Mol Imaging
August 2021
Article Synopsis
- The study aimed to evaluate incidental lung changes in asymptomatic cancer patients using [F]FDG PET/CT during the COVID-19 pandemic in Italy, where the virus was widespread.
- Researchers analyzed data from 59 centers, comparing rates of interstitial pneumonia during various periods: during COVID (March 2020), pre-COVID (January-February 2020), and a control year (2019).
- Results indicated a significant increase in interstitial pneumonia rates during the COVID period (7.1%) compared to pre-COVID (5.35%) and control (5.15%), particularly higher in Northern Italy, emphasizing the need to monitor such findings for early COVID-19 detection and management.
2-[F]fluoro-2-deoxy-d-glucose positron emission tomography (2-[F]FDG-PET) has an emerging supportive role in dementia diagnostic as distinctive metabolic patterns are specific for Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). Previous studies have demonstrated that a data-driven decision model based on the disease state index (DSI) classifier supports clinicians in the differential diagnosis of dementia by using different combinations of diagnostic tests and biomarkers. Until now, this model has not included 2-[F]FDG-PET data.
View Article and Find Full Text PDFBackground: In Alzheimer's disease (AD) diagnosis, both cerebrospinal fluid (CSF) biomarkers and FDG-PET sometimes give inconclusive results.
Objective: To evaluate the incremental diagnostic value of FDG-PET over CSF biomarkers, and vice versa, in patients with mild cognitive impairment (MCI) and suspected AD, in which the first biomarker resulted inconclusive.
Methods: A consecutive series of MCI patients was retrospectively selected from two Memory Clinics where, as per clinical routine, either the first biomarker choice is FDG-PET and CSF biomarkers are only used in patients with uninformative FDG-PET, or vice versa.
Purpose: To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm.
Methods: Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker.
Results: Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P = 0.